- Nano cap Histogenics (HSGX -8.2%) is down on average volume on the heels of its announcement that its discussions with the FDA are continuing regarding the need to generate additional clinical data supporting a potential marketing application for NeoCart in patients with knee cartilage damage.
- The company says it will update investors again when it receives additional feedback from the agency.
- Previously: Histogenics down 45% on announcing results from Phase 3 trial of NeoCart in patients with knee cartilage damage (Sept. 5)